13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • EMBRACE

    Acronym: 

    EMBRACE

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Breast, Gynaecological
    Trial Type Treatment
    Phase Phase II Tumour Stream Breast/Ovarian
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Female Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Breast, Gynaecological
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Female
    Molecular Target
    Tumour Stream Breast/Ovarian
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficiant metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA 1 and BRCA: The EMBRACE study.

    Lay Summary

    Sponsor / Cooperative group

    ANZGOG

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Murray Recruiting